# reload+after+2024-01-22 03:44:19.518736
address1§350 Oyster Point Boulevard
city§South San Francisco
state§CA
zip§94080
country§United States
phone§650 624 3000
fax§650 624 3070
website§https://www.cytokinetics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
fullTimeEmployees§409
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Robert I. Blum', 'age': 59, 'title': 'CEO, President & Director', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 1139075, 'exercisedValue': 7435148, 'unexercisedValue': 48382008}, {'maxAge': 1, 'name': 'Mr. Ching W. Jaw', 'age': 60, 'title': 'Senior VP & CFO', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 698494, 'exercisedValue': 1106000, 'unexercisedValue': 4505503}, {'maxAge': 1, 'name': 'Mr. Robert C. Wong', 'age': 55, 'title': 'VP & Chief Accounting Officer', 'yearBorn': 1968, 'fiscalYear': 2022, 'totalPay': 463747, 'exercisedValue': 0, 'unexercisedValue': 2322550}, {'maxAge': 1, 'name': 'Dr. Fady Ibraham Malik FACC, M.D., Ph.D.', 'age': 59, 'title': 'Executive Vice President of Research & Development', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 776994, 'exercisedValue': 5200986, 'unexercisedValue': 18023516}, {'maxAge': 1, 'name': 'Mr. Andrew M. Callos', 'age': 67, 'title': 'Executive VP & Chief Commercial Officer', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 745398, 'exercisedValue': 0, 'unexercisedValue': 1549599}, {'maxAge': 1, 'name': 'Dr. James A. Spudich Ph.D.', 'age': 81, 'title': 'Co-Founder & Member of Scientific Advisory Board', 'yearBorn': 1942, 'fiscalYear': 2022, 'totalPay': 21938, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jeff  Lotz', 'title': 'Vice President of Sales & Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Steven M. Cook', 'age': 64, 'title': 'Senior Vice President of Supply Chain Operations & Technical Operations', 'yearBorn': 1959, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Diane  Weiser', 'title': 'Senior Vice President of Corporate Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Kari K. Loeser J.D.', 'title': 'VP & Chief Compliance Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§6
boardRisk§3
compensationRisk§5
shareHolderRightsRisk§7
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.733
priceToSalesTrailing12Months§1176.0159
currency§USD
dateShortInterest§1702598400
forwardEps§-4.47
pegRatio§-1.19
exchange§NMS
quoteType§EQUITY
shortName§Cytokinetics, Incorporated
longName§Cytokinetics, Incorporated
firstTradeDateEpochUtc§1083331800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§39e332a5-8990-3a41-9526-4fd099b8f8a6
gmtOffSetMilliseconds§-18000000
targetHighPrice§110.0
targetLowPrice§60.0
targetMeanPrice§87.89
targetMedianPrice§91.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§18
quickRatio§6.97
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
